238 related articles for article (PubMed ID: 25662406)
21. Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy.
Machlenkin A; Paz A; Bar Haim E; Goldberger O; Finkel E; Tirosh B; Volovitz I; Vadai E; Lugassy G; Cytron S; Lemonnier F; Tzehoval E; Eisenbach L
Cancer Res; 2005 Jul; 65(14):6435-42. PubMed ID: 16024648
[TBL] [Abstract][Full Text] [Related]
22. Identification of Lck-derived peptides applicable to anti-cancer vaccine for patients with human leukocyte antigen-A3 supertype alleles.
Naito M; Komohara Y; Ishihara Y; Noguchi M; Yamashita Y; Shirakusa T; Yamada A; Itoh K; Harada M
Br J Cancer; 2007 Dec; 97(12):1648-54. PubMed ID: 18043580
[TBL] [Abstract][Full Text] [Related]
23. Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma.
Wang F; Bade E; Kuniyoshi C; Spears L; Jeffery G; Marty V; Groshen S; Weber J
Clin Cancer Res; 1999 Oct; 5(10):2756-65. PubMed ID: 10537339
[TBL] [Abstract][Full Text] [Related]
24. A phase I clinical trial of CD1c (BDCA-1)+ dendritic cells pulsed with HLA-A*0201 peptides for immunotherapy of metastatic hormone refractory prostate cancer.
Prue RL; Vari F; Radford KJ; Tong H; Hardy MY; D'Rozario R; Waterhouse NJ; Rossetti T; Coleman R; Tracey C; Goossen H; Gounder V; Crosbie G; Hancock S; Diaz-Guilas S; Mainwaring P; Swindle P; Hart DN
J Immunother; 2015; 38(2):71-6. PubMed ID: 25658616
[TBL] [Abstract][Full Text] [Related]
25. Immunological evaluation of neoadjuvant peptide vaccination before radical prostatectomy for patients with localized prostate cancer.
Noguchi M; Yao A; Harada M; Nakashima O; Komohara Y; Yamada S; Itoh K; Matsuoka K
Prostate; 2007 Jun; 67(9):933-42. PubMed ID: 17440952
[TBL] [Abstract][Full Text] [Related]
26. Feasibility study of personalized peptide vaccination for recurrent ovarian cancer patients.
Kawano K; Tsuda N; Matsueda S; Sasada T; Watanabe N; Ushijima K; Yamaguchi T; Yokomine M; Itoh K; Yamada A; Kamura T
Immunopharmacol Immunotoxicol; 2014 Jun; 36(3):224-36. PubMed ID: 24773550
[TBL] [Abstract][Full Text] [Related]
27. Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes.
Slingluff CL; Yamshchikov G; Neese P; Galavotti H; Eastham S; Engelhard VH; Kittlesen D; Deacon D; Hibbitts S; Grosh WW; Petroni G; Cohen R; Wiernasz C; Patterson JW; Conway BP; Ross WG
Clin Cancer Res; 2001 Oct; 7(10):3012-24. PubMed ID: 11595689
[TBL] [Abstract][Full Text] [Related]
28. A phase I study of personalized peptide vaccination using 14 kinds of vaccine in combination with low-dose estramustine in HLA-A24-positive patients with castration-resistant prostate cancer.
Noguchi M; Uemura H; Naito S; Akaza H; Yamada A; Itoh K
Prostate; 2011 Apr; 71(5):470-9. PubMed ID: 20878951
[TBL] [Abstract][Full Text] [Related]
29. Generation of potent cytotoxic T lymphocytes against castration-resistant prostate cancer cells by dendritic cells loaded with dying allogeneic prostate cancer cells.
Hwang EC; Lim MS; Im CM; Kwon DD; Lee HJ; Nguyen-Pham TN; Lee YK; Lee JJ
Scand J Immunol; 2013 Feb; 77(2):117-24. PubMed ID: 23126536
[TBL] [Abstract][Full Text] [Related]
30. [Development of Peptide Vaccines for Triple-Negative Breast Cancer Treatment].
Toh U; Saku S; Okabe M; Iwakuma N; Kimitsuki Y; Akashi M; Ogo E; Yamada A; Shichijo S; Itoh K; Akagi Y
Gan To Kagaku Ryoho; 2016 Oct; 43(10):1249-1251. PubMed ID: 27760950
[TBL] [Abstract][Full Text] [Related]
31. The HER2/neu-derived peptide p654-662 is a tumor-associated antigen in human pancreatic cancer recognized by cytotoxic T lymphocytes.
Peiper M; Goedegebuure PS; Linehan DC; Ganguly E; Douville CC; Eberlein TJ
Eur J Immunol; 1997 May; 27(5):1115-23. PubMed ID: 9174600
[TBL] [Abstract][Full Text] [Related]
32. Identification of SART3-derived peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes from prostate cancer patients with HLA-A3 supertype alleles.
Minami T; Matsueda S; Takedatsu H; Tanaka M; Noguchi M; Uemura H; Itoh K; Harada M
Cancer Immunol Immunother; 2007 May; 56(5):689-98. PubMed ID: 16937115
[TBL] [Abstract][Full Text] [Related]
33. Immunological evaluation of peptide vaccination for cancer patients with the HLA -A11
Sakamoto S; Matsueda S; Takamori S; Toh U; Noguchi M; Yutani S; Yamada A; Shichijo S; Yamada T; Suekane S; Kawano K; Naitou M; Sasada T; Hattori N; Kohno N; Itoh K
Cancer Sci; 2017 Apr; 108(4):598-603. PubMed ID: 28178396
[TBL] [Abstract][Full Text] [Related]
34. [Peptide vaccination for castration-resistant prostate cancer].
Koga N; Noguchi M
Nihon Rinsho; 2014 Dec; 72(12):2147-51. PubMed ID: 25518349
[TBL] [Abstract][Full Text] [Related]
35. Immunological evaluation of CTL precursor-oriented vaccines for advanced lung cancer patients.
Mine T; Gouhara R; Hida N; Imai N; Azuma K; Rikimaru T; Katagiri K; Nishikori M; Sukehiro A; Nakagawa M; Yamada A; Aizawa H; Shirouzu K; Itoh K; Yamana H
Cancer Sci; 2003 Jun; 94(6):548-56. PubMed ID: 12824881
[TBL] [Abstract][Full Text] [Related]
36. A phase I trial of vaccination of CA9-derived peptides for HLA-A24-positive patients with cytokine-refractory metastatic renal cell carcinoma.
Uemura H; Fujimoto K; Tanaka M; Yoshikawa M; Hirao Y; Uejima S; Yoshikawa K; Itoh K
Clin Cancer Res; 2006 Mar; 12(6):1768-75. PubMed ID: 16551861
[TBL] [Abstract][Full Text] [Related]
37. New epitope peptides derived from parathyroid hormone-related protein which have the capacity to induce prostate cancer-reactive cytotoxic T lymphocytes in HLA-A2+ prostate cancer patients.
Yao A; Harada M; Matsueda S; Ishihara Y; Shomura H; Takao Y; Noguchi M; Matsuoka K; Hara I; Kamidono S; Itoh K
Prostate; 2005 Feb; 62(3):233-42. PubMed ID: 15389794
[TBL] [Abstract][Full Text] [Related]
38. Phase II Study of Personalized Peptide Vaccination with Both a Hepatitis C Virus-Derived Peptide and Peptides from Tumor-Associated Antigens for the Treatment of HCV-Positive Advanced Hepatocellular Carcinoma Patients.
Yutani S; Ueshima K; Abe K; Ishiguro A; Eguchi J; Matsueda S; Komatsu N; Shichijo S; Yamada A; Itoh K; Sasada T; Kudo M; Noguchi M
J Immunol Res; 2015; 2015():473909. PubMed ID: 26539554
[TBL] [Abstract][Full Text] [Related]
39. Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC).
Bilusic M; McMahon S; Madan RA; Karzai F; Tsai YT; Donahue RN; Palena C; Jochems C; Marté JL; Floudas C; Strauss J; Redman J; Abdul Sater H; Rabizadeh S; Soon-Shiong P; Schlom J; Gulley JL
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33762322
[TBL] [Abstract][Full Text] [Related]
40. Frequent T cell responses against immunogenic targets in lung cancer patients for targeted immunotherapy.
Babiak A; Steinhauser M; Götz M; Herbst C; Döhner H; Greiner J
Oncol Rep; 2014 Jan; 31(1):384-90. PubMed ID: 24154794
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]